HomeNewsTechnologyMC Interview | Koo co-founder Aprameya Radhakrishna talks about virtual poll campaigns, role of home-grown apps, misinformation and more

MC Interview | Koo co-founder Aprameya Radhakrishna talks about virtual poll campaigns, role of home-grown apps, misinformation and more

In the course of a wide-ranging interview, Koo co-founder Aprameya Radhakrishna, 39, explains how the company has recorded 20 million downloads and has 5,000 eminent members, including chief ministers of 17 States, Union ministers, government departments, and leaders from across the political spectrum

February 21, 2022 / 17:42 IST
Story continues below Advertisement
Koo co-founder Aprameya Radhakrishna
Koo co-founder Aprameya Radhakrishna

With ban on physical rallies in place due to rising COVID-19 cases across the country, political parties had to largely rely on virtual campaigns till the restrictions in the run up to the assembly polls in five states were gradually eased.

Tech-driven election campaigns through the integration of data analytics and social media tools had started in India well before the pandemic, in the 2014 general elections. Today, given the country's 450 million plus social media users, digital platforms are playing a larger role than ever before in election campaigning, more so with the growth of new ventures such as home-grown micro-blogging app Koo.

Story continues below Advertisement

READ | Koo has a Chinese investor who is exiting, says founder Aprameya Radhakrishna

Launched in March 2020, Koo has crossed 20 million downloads and has over 5,000 eminent accounts. In an interview with MoneyControl, Aprameya Radhakrishna, Koo co-founder and Chief Executive Officer (CEO), talks about the evolving role of social media strategies for virtual campaigns, countering misinformation, and how he sees Koo hitting 100 million downloads in the near future. Edited excerpts:

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show